Virpax Pharmaceuticals Inc (VRPX) 銘柄情報

VRPX delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

VRPX................................................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783

Maybe some shorts will close out ? Reverse Split on March 20th of 25:1

$VRPX: Added 50k here at $0.12

Gimme a sweet ass bounce


GO $VRPX

VRPX....................................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783

VRPX....................................................a/h

$VRPX new Start 🗼🗼🗼

$VRPX ✈️🛬✈️
Pre-Market
Shake all panic Sellers
#DayTrading
#nasdaq

seems like the only thing huge about it is dilution.

Guys this is huge.  If you're not familiar with this type of medication (liposomal bupivacaine) , look up PCRX and their very similar medication named Exparel.  Exparel is a mainstay of non opioid pain management and is used in nerve blocks all over the country every day.  The study results are showing that this drug, while similar to exparel, provides pain relief for several days longer than exparel.  With the push to limit opioid, this is going to be huge!  

VRPX........................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783

VRPX: A disruptive, watershed, revolutionary, breakthrough, RATS PAIN study with the US ARMY!!
https://sg.finance.yahoo.com/news/virpax-confirms-positive-results-us-210100632.html
https://www.stocktitan.net/news/VRPX/virpax-confirms-positive-results-with-us-army-with-probudur-tm-for-3kp6uq1rr4kh.html


"I'd like to re-order this PIZZA with pepperoni, mushrooms, anchovies, & VRPX PAIN-KILLERS, please!!"

VRPX: You-dirty-RATS!!! Well, was your PAIN any less when ya-all ate our tasty anti-PAIN pillls??? (Soaring over 100%, behind VRPX's primitive US Army collaboration behind DIRTY-RATS suffering Human-inflicted pain!!) Now please do a PAIN study whereby the RATS inflict the pain on the STUPID-&-DIRTY-HUMANS!!! And see how THEY like it!!! What a PRIMITIVE, IGNORANT, planet we all reside upon!!!!!!


"Let's use Pres. Donald Dumbfuck as the subject in the next VRPX PAIN study, please!!!"

VRPX..............................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783

VRPX moving on nice news https://ih.advfn.com/stock-market/NASDAQ/virpax-pharmaceuticals-VRPX/stock-news/95431147/virpax-confirms-positive-results-with-us-army-with

vrpx......https://stockcharts.com/h-sc/ui?s=Vrpx&p=W&b=5&g=0&id=p86431144783

vrpx.....................https://stockcharts.com/h-sc/ui?s=vrpx&p=W&b=5&g=0&id=p86431144783

VRPX.......................................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783

VRPX.............................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783

VRPX: Q&A reply from COPILOT ---

"VRPX is soaring in the Post-Market right now due to odd EPA extension news allowing VRPX more time to develop their pain drug --- is VRPX a significant player in Human health care?

Virpax Pharmaceuticals Inc. (VRPX) is indeed making strides in the healthcare sector, particularly in the field of pain management. They are developing non-opioid, non-addictive pain management products using proprietary drug-delivery technologies1. Some of their promising preclinical-stage product candidates include:

Epoladerm: A topical spray film delivery technology for osteoarthritis pain.

Probudur: An injectable local anesthetic liposomal gel for postoperative pain management.

Envelta: A nanotechnology-based intranasal spray for delivering a peptide drug to the brain.

AnQlar: An anti-viral barrier to prevent or reduce the risk of viral infections.

NobrXiol: A nasal formulation to enhance cannabidiol transport to the brain.

Their recent announcement about the extension of their cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS) for the development of NES100, an intranasal peptide for managing acute and chronic non-cancer pain, has certainly contributed to the stock's rise.

Would you like to know more about any specific product or their overall strategy?"

VRPX news https://ih.advfn.com/stock-market/NASDAQ/virpax-pharmaceuticals-VRPX/stock-news/94967341/virpax-announces-agreement-with-the-u-s-departmen

VRPX.....https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783

setting up

VRPX...............................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783

VRPX under $2

Any type of Catalyst(s) comes out , which is very likely , this will take off.

VRPX........................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783

Weeeeeeee

vprx...monster pre to open

VRPX: Yep!!! And now PIGS don't have suffer PAIN anymore!!!! (But, what about we HUMANS???!!!)

Virpax Announces Positive Results of Swine Model Pilot Study for Probudur

VRPX: Still kickin' myself for stupidly-misinterpreting their PR as classic FLUFF NEWS. (Which indeed it still was, despite what anybody says!!! WOW!!! they got $2.5-Mil. FINANCING, so they don't fold-up-shop!!! GOD bless them!!!!)

today announced that it has closed a $2.5 million secured loan financing from an institutional investor which enabled the final payment of its litigation settlement. As part of this financing, the Company’s Board of Directors has been reorganized, and has been reduced to seven members from eight. Four new board members have been selected by the institutional investor and appointed to the Board, and five Board members have resigned.

“This loan by the institutional investor, combined with an agreement to negotiate additional funding, will allow us to continue fulfilling our mission to develop non-addictive pain drugs as well as other CNS product candidates with high unmet medical need,” stated Gerald Bruce, CEO of Virpax Pharmaceuticals. “We believe we have a valuable portfolio of assets which was confirmed to us by the high level of interest we received at the recent BIO meeting in San Diego. Our new funding relationship gives us the confidence and flexibility to fund our programs moving forward.”

Additionally, Virpax announced the changes to its Board of Directors with the appointments of Ms. Judy Su, Mr. Gary Herman, Mr. Jatinder Dhaliwal and Ms. Katharyn Field. Resignations from Virpax’s Board were tendered effective upon consummation of the financing by Dr. Jeffrey Gudin, Dr. Thanigavelan Jambulingam, Mr. Michael Dubin, Mr. Jerrold Sendrow and Dr. Barbara Ruskin.

“We are excited to welcome our new Board members whom we anticipate will bring expertise and fresh vision to assist us as we move into our next stage of development. We expect to begin first-in-human trials in 2025,” continued Mr. Bruce.

Ms. Judy Su was lead pharmacist at a national drug store for six years and has knowledge and experience of large-scale retail distribution of scheduled drugs and medications. Currently, Ms. Su works as a pharmacist in the public sector. She has years of experience serving as an independent director for multiple publicly traded companies listed in Canada (CSE,TSX). Judy graduated in 2012 at the University of British Columbia with a bachelor's degree in pharmacy.

Mr. Gary Herman is a seasoned investor. From 2006 until 2021, he co-managed Strategic Turnaround Equity Partners, LP (Cayman), and from 2005 until 2020 he was affiliated with Arcadia Securities LLC. Gary’s expertise extended to his role as a managing member of Abacoa Capital Management, LLC from January 2011 until August 2013, where his focus centered on the Global-Macro investment strategy. His background also includes tenure as an investment banker at Burnham Securities, Inc., a managing partner of Kingshill Group, Inc., and as a director for various public company boards. Mr. Herman received a B.S. in Political Science from the University at Albany, with minors in Business and Music.

Mr. Jatinder (Jay) Dhaliwal is a registered pharmacist and has served as CEO and director of multiple publicly traded companies listed on Canadian (CSE, TSX) and American (Nasdaq) exchanges. Mr. Dhaliwal is currently a director of a Nasdaq listed leading seed to patient cannabis producer in Europe as well as serving as an independent director of a Nasdaq listed premier marketing agency specialized in the liquor industry. Previously, he worked in an upper management role in a large national pharmacy and has extensive knowledge in agricultural, medical and pharmaceutical operations. Mr. Dhaliwal holds a Bachelor of Pharmacy from the University of British Columbia and a Bachelor of Science in biology from the University of Victoria.

Ms. Katharyn (Katie) Field’s background includes positions spanning both the private and public sectors and brings a wealth of experience and expertise in strategy consulting and executive leadership. Ms. Field is currently the CEO and Chairman of Halo Collective Inc., an Executive Director at Akanda Corporation, and the Chairperson of Aerwins Technology. She has held prominent positions at renowned organizations including in the White House in the office of the public liaison, the Brookings Institution as a manager of operations, and Bain & Company as a consultant. In 2014, Ms. Field entered the cannabis industry working with one of the original vertically integrated licensed medical marijuana treatment centers in Florida. Subsequently, she operated a strategy consulting practice focused on cannabis and served as Executive Vice President of Corporate Development at MariMed from 2018 to 2019. Ms. Field holds an MBA from Columbia Business School and a BA with honors from Stanford University.

“We are grateful to the outgoing Board members and thank them for their support and contributions,” concluded Mr. Bruce.

About Virpax Pharmaceuticals

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage severe pain, including post cancer pain. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop one other prescription product candidate, NobrXiol™, which is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is also seeking approval of two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube.

Not a bad day

tint float with news

VRPX......................................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783

VRPX: effective March 1,2024 a one for 10 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

VRPX...........................................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783

whats the latest here? https://finviz.com/quote.ashx?t=VRPX&ty=c&ta=1&p=d

“ Litigation

From time to time the Company is subject to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

On March 12, 2021, the Company and Mr. Mack (the “Defendants”) were named as defendants in a complaint (the “Complaint”) filed by Sorrento Therapeutics, Inc. (“Sorrento”), and Scilex Pharmaceuticals Inc. (“Scilex” and together with Sorrento, the “Plaintiffs”) in the Court of Chancery of the State of Delaware. In the Complaint, the Plaintiffs alleged (i) Mr. Mack breached a Restrictive Covenants Agreement, dated as of November 8, 2016, between himself and Sorrento (the “Restrictive Covenants Agreement”), (ii) the Company tortiously interfered with the Restrictive Covenants Agreement, and (iii) the Company tortiously interfered with Scilex’s relationship with Mr. Mack. On May 7, 2021 Plaintiffs filed an Amended Complaint (the “First Amended Complaint”) asserting the same three causes of action. Simultaneously with filing the original Complaint, Plaintiffs filed a motion to expedite, seeking a hearing on their prospective motion for a preliminary injunction, prohibiting Mr. Mack’s alleged violations of the Restrictive Covenants Agreement and prohibiting the alleged tortious interference. On March 22, 2021, Vice Chancellor Paul A. Fioravanti Jr. issued a scheduling order, setting forth terms which had been agreed to by the parties, under which oral argument on Plaintiffs’ proposed motion for preliminary injunction was scheduled for July 15, 2021. On May 18, 2021, the Vice Chancellor issued a revised scheduling order, also setting forth terms which had been agreed to by the parties, under which Plaintiffs agreed not to move for a preliminary injunction and a trial in the action was set for February 9-11, 2022. On September 28, 2021, Plaintiffs filed a Second Amended Verified Complaint asserting the same three causes of action as the prior complaints, as well as additional claims in which Plaintiffs allege (i) Mr. Mack breached an Employment, Proprietary Information and Inventions Agreement, dated as of October 25, 2016, between himself and Sorrento (the “Employment Agreement”), (ii) the Company tortiously interfered with the Employment Agreement, (iii) Mr. Mack breached his fiduciary duties to Scilex, and (iv) the Company aided and abetted Mr. Mack’s alleged breach of fiduciary duties to Scilex. On October 18, 2021, Defendants filed an Answer to the Second Amended Complaint, and subsequently withdrew a previously filed motion to dismiss the first Amended Complaint. We intend to vigorously defend the action. However, we are unable to predict the ultimate outcome of the lawsuit at this time.
“

- From the quarterly filing

News

Adding here

Company just screwed existing share holders with a $6.00 placement. Shame on you./ok2

Halted this morning pending news. On my watchlist./ok2

Back in on the buy, thanks to the seller./ok2

Also extremely low float on this one. Big money looking to steal your shares today if you let them./ok2

I see the games are afoot here. Large asks coming into the block, looking to scare retailers holding the stock into selling lower. Don't be intimidated by institutions into selling your shares because they are buying them./ok2

Oversold on a Friday. Bought and will hold into next week. Good luck to all./ok2buy

VRPX - MIDDAY REPORT

Another SCAM play? lolzzzzzz